Futura Medical plc is a UK-based public limited company specializing in the development and global commercialization of innovative sexual health products. Its lead product, Eroxon®, represents a clinically proven breakthrough treatment for erectile dysfunction (ED), designed as an over-the-counter (OTC) solution to enhance quality of life. The company focuses on proprietary technologies in the sexual health sector, particularly for men's health, with a strategy centered on partnering with leading consumer healthcare firms to leverage their marketing expertise and resources for effective consumer engagement. Incorporated in 2001 and headquartered at the Surrey Technology Centre in Guildford, United Kingdom, Futura Medical plc operates within the biotechnology and human health activities domain (SIC 86900). By prioritizing clinically validated products, it addresses unmet needs in the OTC market, contributing to advancements in accessible sexual wellness solutions while delivering long-term value to shareholders through strategic collaborations.